Norliqva (Amlodipine Besylate) Patent Expiration, LOE Window & CMS Spending

Norliqva (Amlodipine Besylate) by Cmp Development: FDA Orange Book LOE 2041-02-24, 19 AB generics, $2.0M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCmp Development
FDA Application & PathwayN214439 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2041-02-24
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$2.0M
2024 Medicare Part D Spend$636K
2024 Medicaid Spend$1.4M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel